

**Sun Pharmaceutical Industries Limited**  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



**February 5, 2024**

**National Stock Exchange of India Limited**  
NSE Code: SUNPHARMA

**BSE Limited**  
BSE Code: 524715

**Subject - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of a Subsidiary Company**

---

This is to inform that a subsidiary company with the name Taro Pharma Corporation, Inc. (USA) is incorporated on February 5, 2024 as a wholly-owned subsidiary of Taro Pharmaceutical Industries Ltd. (Israel), a subsidiary of the Company.

Particulars of the disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III are provided in the **Annexure A**.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary & Compliance Officer**  
ICSI Membership No.: A23983

**Annexure A**

**Disclosure under sub-para (1) i.e. Acquisition(s) (including agreement to acquire) of Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Sl. No.	Particulars	Information
1	Name of the target entity, details in brief such as size, turnover etc.;	Taro Pharma Corporation, Inc. (“Taro Pharma Corporation”) incorporated on February 5, 2024 as a wholly-owned subsidiary of Taro Pharmaceutical Industries Ltd. (“Taro Israel”), a subsidiary of the Company. The registered address of Taro Corporation is situated at 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	Taro Pharma Corporation is a newly incorporated company and therefore, it is not a related party transaction.
3	Industry to which the entity being acquired belongs;	Pharmaceutical
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Taro Pharma Corporation is set up as an entity separate from Alchemee LLC, a subsidiary of Taro Israel, to help Alchemee LLC with selling its Proactiv skincare products on e-commerce marketplace in USA.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	None
6	Indicative time period for completion of the acquisition;	Not applicable as this intimation is about a newly incorporated subsidiary company.
7	Nature of consideration - whether cash consideration or share swap and details of the same;	Initial capital subscription in cash.
8	Cost of acquisition or the price at which the shares are acquired;	Not applicable, as this intimation is about a newly incorporated subsidiary company.
9	Percentage of shareholding/ control acquired and/ or number of shares acquired;	Taro Israel will own 100% equity interest of Taro Corporation.  The Company holds 78.48% in Taro Israel through its other subsidiaries.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Not applicable, as this intimation is about a newly incorporated subsidiary company.